Phase III BELLINI: Updated Results With Venetoclax or Placebo Plus Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

May 29-31, 2020; Online at
Venetoclax plus bortezomib/dexamethasone was selectively associated with favorable survival outcomes in patients with R/R myeloma and the t(11;14) cytogenetic marker in this updated study analysis.
Format: Microsoft PowerPoint (.ppt)
File Size: 221 KB
Released: June 2, 2020


Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by educational grants from
AbbVie Inc.
Bristol-Myers Squibb
Karyopharm Therapeutics

Related Content

Interactive online tool providing expert treatment recommendations for newly diagnosed and relapsed/refractory follicular lymphoma from CCO

John M. Burke, MD Ian W. Flinn, MD, PhD Christopher R. Flowers, MD, MS John P. Leonard, MD Jeff P. Sharman, MD Released: March 1, 2021

Clinical Care Options (CCO) expert podcast of top leukemia presentations from Hematology 2020: magrolimab in AML, asciminib in CML (ASCEMBL), ponatinib dosing in CML (OPTIC)

Jorge Cortes, MD Eunice S. Wang, MD Released: February 26, 2021

From Clinical Care Options (CCO), Drs. Jeff Sharman and John Burke review key data from studies of lymphomas and CLL treatment presented at ASH 2020

John M. Burke, MD Jeff P. Sharman, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: February 26, 2021 Expired: February 25, 2022

Drs. Amy DeZern and Srdan Verstovsek discuss their top abstract choices from ASH 2020 in MDS and MPNs, from Clinical Care Options (CCO)

Amy E. DeZern, MD, MHS Srdan Verstovsek, MD, PhD Released: February 23, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.